GLAUKOS Corp
About GLAUKOS Corp
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite for glaucoma treatment and other platforms including retinal XR for age-related macular degeneration. Founded in 1998 and headquartered in Aliso Viejo, CA, it is a public company listed on NYSE.
Investors
Key highlights
- Completed IPO in June 2015 at $18 per share with lead underwriters JP Morgan, BofA and Goldman Sachs.
- Developed iStent family of micro-bypass stents for physiologic treatment of open-angle glaucoma.
- Raised $284.20M total across 11 private rounds prior to going public.
- Headquartered in Aliso Viejo, CA with 38,595 LinkedIn followers as a public medical device company.
- Focuses on therapies for glaucoma, corneal disorders and retinal diseases including the retinal XR platform.
Ask StreetZero about GLAUKOS Corp
Put our AI to work on this deal.
Similar companies
Other Public Equity (NYSE) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account